It wasn't worth then it is worth now. If you look at almost every big pharma's earnings these days, with flat to decline revenue in Europe due to pricing pressure, it is clear they depend on emerging markets more and more. This trend will continue when pricing pressure will come to US eventually. Those who don't see the trend will suffer in the future. Even traditional biotech like Amgen is doing emerging market acquisition.
Market Data 
Markets 
AI
